Advertisement: Simpsons Creative
Advertisement: RSM mid banner
Advertisement: CJBS mid banner
Advertisement: partnersand mid banner
Cambridgeand mid banner advertisement
Barr Ellison Solicitors – commercial property
Advertisement: Kao Data Centre mid banner
Advertisement: Bar Ellison mid banner property
Advertisement: EBCam mid banner
ARM Innovation Hub
Advertisement mid banner S-Tech 1
Advertisement: Cambridge Network mid banner
Advertisement: Excalibur Healthcare mid banner
Advertisement: Mogrify mid banner
Mid banner advertisement: BDO
Advertisement: HCR Hewitsons mid banner
Advertisement: SATAVIA mid banner
26 January, 2022 - 20:50 By Tony Quested

Nuclera scales with new Boston US subsidiary

Nuclera, a Cambridge Science Park company developing cutting-edge benchtop protein printing technologies, has launched a US subsidiary in Boston.

The addition of the facility in the rapidly growing biotech hub of greater Boston is a critical step in the company’s plans, paving the way for Nuclera’s revolutionary eProteinTM desktop bioprinter.

The technology is said to offer unprecedented speed and convenience for biotherapeutics, agribiotech and other markets of global importance. Nuclera’s eProtein™ bioprinter is born out of a strategic partnership with E Ink – a pioneer of ePaper – allowing the combination of biopolymer synthesis technologies with digital microfluidics.

The US facilities are the result of a $4.5 million E Ink renovation, reinforcing Nuclera’s position as a technological innovator in the bioprinting space. 

Dr Michael Chen, CEO and co-founder of Nuclera, said: “Our new laboratories and pilot manufacturing facilities in Boston will support Nuclera’s goal to commercialise its eProtein™ technology – significantly accelerating drug discovery workflows. 

“This site opening just outside one of the most important biotech markets is a big step towards Nuclera’s goal to make proteins accessible through desktop bioprinting. 

“The facility has been specifically designed to accommodate our expanding team and will support Nuclera’s ambitious roadmap. We are proud to have operations in both the UK and US, further strengthening our position in the global biotech space.”

As part of Nuclera’s global expansion, Richard Paolini Jr, has been appointed VP of eDropTM R & D, the first of many US-based appointments. With over 20 years of R & D experience, Rick is an inventor named on over 100 US patents on technologies that have helped E Ink to enable and transform the eReader market.

He is now leading the development of closely related technologies to enable Nuclera’s eDropTM digital microfluidic systems – requiring integration of complex chemical, biological, electronic, and mechanical elements.

Dr Michael McCreary, E Ink’s chief innovation officer and board director said: “E Ink is very excited about the continuing collaboration and partnership with Nuclera in this expanding biotechnology market sector that is of such global importance. 

“The transfer of Rick and his talented microfluidics team of scientists from E Ink to Nuclera and the renovation of the US-based biotechnology R & D centre that Nuclera will occupy will ensure ongoing biotechnology advancements leading to a successful commercial launch of the Nuclera eProtein platform.”

Newsletter Subscription

Stay informed of the latest news and features